ICCC

Company Overview — What Does IMMUCELL CORP /DE/ Do?

ImmuCell Corporation, an animal health company, develops, manufactures, and markets products that enhance the health and productivity of dairy and beef cattle in the United States and internationally. It offers First Defense, an orally delivered scours preventive product for newborn dairy and beef calves; and Tri-Shield First Defense, a passive antibody product for the treatment of E. coli, coronavirus, and rotavirus. The company also provides California Mastitis Test that is used to detect somatic cell counts in milk, as well as to determine, which quarter of the udder is mastitic; and Dual-Force First Defense, including a whey protein concentrate for the nutritional and feed supplement markets. In addition, it is involved in developing Re-Tain, a Nisin-based intramammary treatment of subclinical mastitis in lactating dairy cows. It sells its products through animal health distributors. ImmuCell Corporation was incorporated in 1982 and is headquartered in Portland, Maine. IMMUCELL CORP /DE/ (ICCC) is classified as a micro-cap stock in the Healthcare sector, specifically within the Pharmaceutical Products industry. The company is led by CEO Michael F. Brigham and employs approximately 70 people, headquartered in Portland, Maine. With a market capitalization of $57M, ICCC is one of the notable companies in the Healthcare sector.

IMMUCELL CORP /DE/ (ICCC) Stock Rating — Hold (April 2026)

As of April 2026, IMMUCELL CORP /DE/ receives a Hold rating with a composite score of 44.6/100 and 3 out of 5 stars from the Blank Capital Research quantitative model.ICCC ranks #712 out of 4,446 stocks in our coverage universe. Within the Healthcare sector, IMMUCELL CORP /DE/ ranks #46 of 838 stocks, placing it in the top 10% of its Healthcare peers. The rating is generated by a multi-factor model that weighs quality (30%), momentum (25%), value (15%), investment (10%), stability (10%), and short interest (10%).

ICCC Stock Price and 52-Week Range

IMMUCELL CORP /DE/ (ICCC) currently trades at $7.08. The stock lost $0.12 (1.6%) in the most recent trading session. The 52-week high for ICCC is $7.60, which means the stock is currently trading -6.9% from its annual peak. The 52-week low is $4.52, putting the stock 56.5% above its annual trough. Recent trading volume was 17K shares, suggesting relatively thin trading activity.

Is ICCC Overvalued or Undervalued? — Valuation Analysis

IMMUCELL CORP /DE/ (ICCC) carries a value factor score of 46/100 in the Blank Capital model, indicating fair valuation relative to historical norms. The trailing price-to-earnings ratio is 53.92x, compared to the Healthcare sector average of 23.63x — a premium of 128%. The price-to-book ratio stands at 2.21x, versus the sector average of 2.75x. The price-to-sales ratio is 2.29x, compared to 1.66x for the average Healthcare stock. On an enterprise value basis, ICCC trades at 60.76x EV/EBITDA, versus 6.34x for the sector.

Overall, ICCC's valuation appears roughly in line with sector benchmarks, suggesting the market is pricing the stock fairly given its current fundamentals and growth trajectory. Neither deep value nor significantly overpriced, the stock occupies a middle ground on valuation.

IMMUCELL CORP /DE/ Profitability — ROE, Margins, and Quality Score

IMMUCELL CORP /DE/ (ICCC) earns a quality factor score of 42/100, signaling below-average profitability metrics relative to the broader market. The return on equity (ROE) is 4.1%, compared to the Healthcare sector average of -43.5%, which is below typical expectations for high-quality companies. Return on assets (ROA) comes in at 2.6% versus the sector average of -33.1%.

On a margin basis, IMMUCELL CORP /DE/ reports gross margins of 38.6%, compared to 71.5% for the sector. The operating margin is 3.4% (sector: -66.1%). Net profit margin stands at 2.9%, versus -58.7% for the average Healthcare stock. Revenue growth is running at 0.6% on a trailing basis, compared to 10.6% for the sector. Profitability is below benchmark levels, which may reflect industry headwinds, elevated reinvestment, or structural challenges.

ICCC Debt, Balance Sheet, and Financial Health

IMMUCELL CORP /DE/ has a debt-to-equity ratio of 34.0%, compared to the Healthcare sector average of 32.0%. The low leverage indicates a conservative balance sheet with significant financial flexibility. The current ratio is 4.26x, indicating strong short-term liquidity. Total debt on the balance sheet is $9M. Cash and equivalents stand at $4M.

ICCC has a beta of 0.30, meaning it is less volatile than the S&P 500, making it a relatively defensive holding. The stability factor score for IMMUCELL CORP /DE/ is 58/100, reflecting average volatility within the normal range for its sector.

IMMUCELL CORP /DE/ Revenue and Earnings History — Quarterly Trend

In TTM 2026, IMMUCELL CORP /DE/ reported revenue of $26M and earnings per share (EPS) of $-0.12. Net income for the quarter was $1M. Gross margin was 38.6%. Operating income came in at $1M.

In FY 2025, IMMUCELL CORP /DE/ reported revenue of $28M and earnings per share (EPS) of $-0.12. Net income for the quarter was $-1M. Gross margin was 41.4%. Revenue grew 4.3% year-over-year compared to FY 2024. Operating income came in at $2M.

In Q3 2025, IMMUCELL CORP /DE/ reported revenue of $6M and earnings per share (EPS) of $-0.02. Net income for the quarter was $-139,748. Gross margin was 42.9%. Revenue grew -8.4% year-over-year compared to Q3 2024. Operating income came in at $20,075.

In Q2 2025, IMMUCELL CORP /DE/ reported revenue of $6M and earnings per share (EPS) of $0.06. Net income for the quarter was $501,880. Gross margin was 43.7%. Revenue grew 17.8% year-over-year compared to Q2 2024. Operating income came in at $569,562.

Over the past 8 quarters, IMMUCELL CORP /DE/ has demonstrated a growth trajectory, with revenue expanding from $5M to $26M. Investors analyzing ICCC stock should weigh these quarterly trends alongside the valuation and quality metrics discussed above.

ICCC Dividend Yield and Income Analysis

IMMUCELL CORP /DE/ (ICCC) does not currently pay a dividend. This is common among smaller companies in the Pharmaceutical Products industry that prefer to reinvest cash flows into business expansion rather than returning capital to shareholders. Income-focused investors looking for Healthcare dividend stocks may want to explore other Healthcare stocks or use the stock screener to filter by dividend yield.

ICCC Momentum and Technical Analysis Profile

IMMUCELL CORP /DE/ (ICCC) has a momentum factor score of 51/100, reflecting neutral trend characteristics. The stock is neither significantly outperforming nor underperforming the broader market on a momentum basis. The investment factor score is 33/100, which measures capital allocation efficiency and asset growth patterns. The short interest score of 31/100 signals elevated short interest, which can indicate bearish sentiment among institutional investors.

ICCC vs Competitors — Healthcare Sector Ranking and Peer Comparison

Within the Healthcare sector, IMMUCELL CORP /DE/ (ICCC) ranks #46 out of 838 stocks based on the Blank Capital composite score. This places ICCC in the top decile of all Healthcare stocks in our coverage universe. Key competitors and sector peers include ASTRAZENECA PLC (AZN) with a score of 61.4/100, Sol-Gel Technologies Ltd. (SLGL) with a score of 56.6/100, VIEMED HEALTHCARE, INC. (VMD) with a score of 53.4/100, Innoviva, Inc. (INVA) with a score of 52.7/100, and JOHNSON & JOHNSON (JNJ) with a score of 51.7/100.

Comparing ICCC against the S&P 500 benchmark is also instructive for understanding relative performance. Investors can view the full ICCC vs S&P 500 (SPY) comparison to assess how IMMUCELL CORP /DE/ stacks up against the broader market across all factor dimensions.

ICCC Next Earnings Date

No upcoming earnings date has been announced for IMMUCELL CORP /DE/ (ICCC) at this time. Check the earnings calendar for the latest scheduling updates across all stocks in our coverage universe.

Should You Buy ICCC? — Investment Thesis Summary

IMMUCELL CORP /DE/ presents a balanced picture with arguments on both sides.

In summary, IMMUCELL CORP /DE/ (ICCC) earns a Hold rating with a composite score of 44.6/100 as of April 2026. The rating is derived from the Blank Capital Research methodology, which combines six factor dimensions into a single quantitative ranking. Investors should consider these quantitative signals alongside their own fundamental research, risk tolerance, and investment time horizon before making buy or sell decisions on ICCC stock.

Related Resources for ICCC Investors

Explore more research and tools: ICCC vs S&P 500 comparison, top Healthcare stocks, stock screener, our methodology, quality factor explained, value factor explained, momentum factor explained. Compare ICCC head-to-head with peers: ICCC vs AZN, ICCC vs SLGL, ICCC vs VMD.